Objective: To study the relationship between surgical management and prognosis of adrenocortical carcinoma (ACC) in order to guide the surgical management of ACC. Methods: Clinical data of 45 cases of ACC treated in our hospital were retrospectively analyzed. The 45 cases included 3 cases in stage I, 12 cases in stage II, 7 cases in stage III, and 23 cases in stage IV. 17 cases underwent complete excision, 14 cases underwent palliative excision, 8 cases had non-operative treatment and 6 cases gave up treatment. All patients were followed up from 2 to 141 months. Results: The average survival time of 31 patients with surgery was 32.46 months, and the average survival time of 14 patients without surgery was 4.75 months. There were statistically significant differences between the two groups (p < 0.01). There were no statistically significant differences between the two groups in survival time in stage III and stage IV (p > 0.05). Conclusions: Surgery is considered to be the only method to cure ACC. For ACC in stage I and II, tumor resection is the most effective treatment, and second surgical operation is recommended for local recurrence. For ACC in stage III, extensive surgical operation is recommended, and for ACC in stage IV, surgical operation has no effect on the prognosis.

Keywords:
Adrenocortical carcinoma, Surgery, Prognosis, Stages I–IV
1.
Icard P, Chapuis Y, Andreassian B, et al: Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992;112:972–979.
2.
Lee JE, Berger DH, el-Naggar AK, et al: Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 1995;118:1090–1098.
3.
Rodgers SE, Evans DB, Lee JE, et al: Adrenocortical carcinoma. Surg Oncol Clin N Am 2006;15:535–553.
4.
Van Ditzhuijsen CI, van de Weijer R, Haak HR: Adrenocortical carcinoma. Neth J Med 2007;65:55–60.
5.
Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al: Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000;88:711–736.
6.
Shaikh AH, Khalid SE, Junejo NN: Adrenocortical carcinoma with endocrine syndromes. J Coll Physicians Surg Pak 2007;17:694–696.
7.
Chouairy CJ, Abdul-Karim F, MacLennan GT: Adrenocortical carcinoma. J Urol 2008;179:323.
8.
Fulmer BR: Diagnosis and management of adrenal cortical carcinoma. Curr Urol Rep 2007;8:77–82.
9.
Assié G, Antoni G, Tissier F, et al: Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2007;92:148–154.
10.
Ohwada S, Izumi M, Kawate S, et al: Surgical outcome of stage III and IV adrenocortical carcinoma. Jpn J Clin Oncol 2007;37:108–113.
11.
Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Führer D, Jurowich C, Quinkler M, Petersenn S, Spahn M, Hahner S, Allolio B, German ACC Registry Group: Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010;95:4925–4932.
12.
Kendrick ML, Lloyd R, Erickson L, Farley D, Grant CS, Thompson GB, Rowland C, Young WF Jr, van Heerden JA: Adrenocortical carcinoma: surgical progress or status quo? Arch Surg 2001;136:543–549.
13.
Wängberg B, Khorram-Manesh A, Jansson S, Nilsson B, Nilsson O, Jakobsson CE, Lindstedt S, Odén A, Ahlman H: The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer 2010;17:265–272.
14.
Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A: Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 2006;30:872–878.
15.
Satter EK, Barnette DJ: Adrenocortical carcinoma with delayed cutaneous metastasis. J Cutan Pathol 2008;35:677–680.
16.
Zardi EM, Santini D, Vincenzi B, et al: Surgical complications after resection of adrenal carcinoma. J Exp Clin Cancer Res 2006;25:449–451.
17.
Terzolo M, Berruti A: Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes 2008;15:221–226.
18.
Bertherat J, Coste J, Bertagna X: Adjuvant mitotane in adrenocortical carcinoma. N Engl J Med 2007;357:1257–1258.
19.
Fareau GG, Lopez A, Stava C, et al: Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies. Anticancer Drugs 2008;19:637–644.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.